List of Excipients in Branded Drug DOXORUBICIN HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	0069-3030	HYDROCHLORIC ACID
Pfizer Laboratories Div Pfizer Inc	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	0069-3030	SODIUM CHLORIDE
Pfizer Laboratories Div Pfizer Inc	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	0069-3030	WATER
Pfizer Laboratories Div Pfizer Inc	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	0069-4004	HYDROCHLORIC ACID

Generic Drugs Containing DOXORUBICIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9084	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9084	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9084	WATER
Hikma Pharmaceuticals USA Inc	doxorubicin hydrochloride	0143-9088	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in DOXORUBICIN HYDROCHLORIDE?

# Of NDCs	Excipient
18	AMMONIUM SULFATE
18	CHOLESTEROL
15	HISTIDINE
27	HYDROCHLORIC ACID

Excipient Strategy and Commercial Opportunities for Doxorubicin Hydrochloride

Last updated: February 26, 2026

What are the key excipient considerations for Doxorubicin Hydrochloride?

Doxorubicin Hydrochloride (Adriamycin) is an anthracycline antibiotic used predominantly in chemotherapy for various cancers. Its formulation involves several excipients to ensure stability, solubility, and compatibility, with specific considerations tailored to its cytotoxic nature.

Common excipients include:

• Sodium chloride and dextrose for dilution.
• Sodium bicarbonate to neutralize acidity.
• Polysorbate 80 (Tween 80) as a solubilizer.
• Buffering agents like citrate or acetate buffers to maintain pH.

Excipients are selected based on their ability to prevent aggregation, reduce degradation, and minimize toxicity. Compatibility testing guides excipient choices to prevent chemical interactions that could degrade the active pharmaceutical ingredient (API).

How does excipient choice influence formulation stability?

Doxorubicin Hydrochloride's stability is sensitive to pH, light, and temperature. Excipients can modify stability by:

• Maintaining optimal pH (around 4.0-6.0) to reduce hydrolysis.
• Using antioxidants like ascorbic acid to prevent oxidative degradation.
• Incorporating chelating agents such as EDTA to sequester metal ions catalyzing oxidation.

Excipients must not adversely interact with doxorubicin, which can cause precipitation or chemical decomposition, leading to reduced efficacy or increased toxicity.

What are the challenges and opportunities for excipient innovations?

Challenges include:

• Minimizing excipients that cause hypersensitivity or infusion reactions.
• Ensuring compatibility across various delivery systems, such as IV bags.
• Managing excipient transparency in regulatory submissions.

Opportunities involve:

• Developing lipid-based formulations to reduce excipient load.
• Using polymer conjugates to bypass some excipient-related limitations.
• Engineering targeted delivery systems with minimal excipient content to improve side-effect profiles.

Advances in nanoformulations and liposomal encapsulation suggest pathways to reduce excipient burden, potentially expanding market access.

What are the commercial implications of excipient strategies?

Excipient selection impacts manufacturing scalability and regulatory approval timelines. Utilizing novel excipients or delivery systems can differentiate products, allowing premium pricing and extended patent protection.

Regulatory agencies scrutinize excipient safety profiles, especially for oncology drugs administered intravenously. Formulations with well-characterized excipients have a smoother pathway to approval.

Developing formulations with reduced excipient complexity lowers manufacturing costs and logistical burdens, which translates to enhanced margins.

Which market segments offer growth based on excipient strategy?

Key segments include:

• Liposomal formulations: liposomal doxorubicin (e.g., Doxil) reduces excipient-related toxicity. Market size exceeded USD 1 billion globally in 2021[1].
• Bioconjugates: antibody-drug conjugates (ADCs) encapsulating doxorubicin provide targeted therapy, with complex excipient systems to ensure stability.
• Generic market expansion: formulators adopting existing excipient strategies to accelerate generic approvals.

Increased demand for safer, more effective formulations encourages innovation in excipient selection, potentially generating high-value licensing opportunities.

What regulatory trends influence excipient use in Doxorubicin formulations?

Regulators demand detailed excipient safety data, especially for chronic or high-dose regimens. The US FDA has guidance documents emphasizing excipient safety in parenteral drugs [2].

Approval pathways favor formulations with Generally Recognized As Safe (GRAS) excipients, but for advanced delivery systems, novel excipients may be required, which prolongs approval periods but offers competitive differentiation.

Post-market surveillance of excipient-related adverse events influences formulation development strategies, focusing on excipients with well-established safety profiles.

Key Takeaways

• Excipient strategies for doxorubicin involve stabilizing agents, solubilizers, pH buffers, and antioxidants.
• Innovations focus on reducing toxicity, improving stability, and enabling targeted delivery.
• Custom formulation approaches can create competitive advantages; regulatory compliance remains critical.
• Liposomal and bioconjugate formulations dominate growth prospects.
• Safety and compatibility considerations are central to excipient selection, impacting regulatory and commercial success.

FAQs

1. Can excipient modifications increase doxorubicin stability?
Yes. Adjusting pH, adding antioxidants, or chelating agents enhances stability by reducing hydrolysis and oxidation.

2. Are there excipient alternatives to polysorbate 80?
Yes. Plant-based surfactants or new polymer stabilizers are under development to reduce hypersensitivity risks associated with polysorbate 80.

3. How does excipient choice affect patentability?
Formulations with novel excipient combinations can be patented, providing market exclusivity.

4. What role do excipients play in reducing side effects?
Excipients like liposomes or targeted conjugates limit exposure to non-cancerous tissues, decreasing adverse events.

5. How does the regulatory landscape impact excipient development?
Strict safety assessments and approval pathways influence excipient selection, favoring those with established safety profiles.

---

References

[1] MarketWatch. (2021). Liposomal doxorubicin market size.

[2] US Food and Drug Administration. (2019). Guidance for Industry: Considerations for Development of Parenteral Drugs and Biologics with Novel Excipients.